SCHEMBL1355170

SCHEMBL1355170

COc1ccc(-n2ncc3cnc(Nc4ccc(N5CCOCC5)cc4)nc32)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF2AK4 Q9P2K8 1/20 0.61
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
CSF1R P07333 4/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
FGFR4 P22455 2/20 0.55
CDK4 P11802 4/20 0.54
CCND1 P24385 3/20 0.54
CDK1 P06493 2/20 0.54
CCNB1 P14635 2/20 0.54
CCNE1 P24864 2/20 0.54
CDK2 P24941 2/20 0.54
LCK P06239 1/20 0.54
TBK1 Q9UHD2 1/20 0.54
CCND2 P30279 1/20 0.53
CCND3 P30281 1/20 0.53
DAPK1 P53355 2/20 0.53
MERTK Q12866 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355752 0.91 EIF2AK4 (0.62) EIF2AK4NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL1355852 0.90 FGFR4 (0.63) EIF2AK4NPC1RAB9ASMN1; SMN2CSF1R
SCHEMBL1353760 0.90 EGFR (0.65) EIF2AK4FGFR4CDK4CCND1CDK1
SCHEMBL1353701 0.89 EIF2AK4 (0.60) EIF2AK4FGFR4CDK4CCND1CDK1
SCHEMBL1355600 0.86 SYK (0.54) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL1355679 0.85 FGFR4 (0.56) EIF2AK4FGFR4CDK4CDK2TBK1
SCHEMBL1356186 0.84 EIF2AK4 (0.67) EIF2AK4CSF1RMEN1KMT2ACDK4
SCHEMBL1356007 0.84 EIF2AK4 (0.67) EIF2AK4CSF1RMEN1KMT2ACDK4
SCHEMBL1353591 0.83 EIF2AK4 (0.56) EIF2AK4NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL1355806 0.83 EIF2AK4 (0.56) EIF2AK4NPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US claimed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US disclosed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US disclosed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP disclosed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885NPC1 2447/4885RAB9A 2076/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885NPC1 2447/4885RAB9A 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.